Revenues for the first half of 2022 and update on AB Science’s activities
30/09/2022 – AB Science today reports its revenues for the first half of 2022 and provides an update on its activities
30/09/2022 – AB Science today reports its revenues for the first half of 2022 and provides an update on its activities
14/09/2022 – AB Science announced continuation of the Phase 2 study evaluating the antiviral activity of masitinib in patients who have a confirmed diagnosis of COVID-19, following the recommendation of the Data and Safety Monitoring Board (DSMB)